Abstract: The 3TC resistance mutations rtL180M and rtM204V were observed in 10 (47.6%) of the 21 patients, while 5 patients (23.8%) had rtV173L, rtL180M and rtM204V mutations.
Introduction: However, it has been shown that HBV resistance to 3TC occurs rapidly through the rtM204V/I substitutions.
Discussion: Although there were differences in genotype, the dominant pattern of resistance among treatment-experienced patients with mutated strains, (rtM204V + rt
Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.
Abstract: All subjects with virological rebound (n=5) showed drug-resistant mutation: three had mutation rtM204I, and two had mutation rtM204V.
Result: All five patients with virological rebound had evidence of drug-resistant mutations, with three patients with the rtM204I mutation and two with the rtM204V mutation.
Genotyping of HBV and tracking of resistance mutations in treatment-naive patients with chronic hepatitis B.
Discussion: One of the resistance mutations found in the Northeastern Region was rtA194T, which can be associated with resistance to TDF, which has shown in vitro reduced susceptibility to TDF when combined with the resistance mutations to LAM M204V and L180M.
Discussion: The other two mutations are associated with resistance to LAM rtL180M + rtM204V and rtS202I.
Discussion: The resistance mutations rtL180M + rtM204V and rtS202I
HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining.
Discussion: Furthermore, in vitro studies showed that substitutions rtS202R and rtM250K would severely impair the replication capability of HBV variants with LAM resistance substitutions (rtL180M + rtM204V), while substitution rtS202T played only a minor role in ETV resistance.
Discussion: It has been related to ETV resistance in the presence of the rtM204V + rtL180M backbone.
Discussion: This suggests that these atypical substitutions might not play important roles in the emergence of NUCr a
The burden of hepatitis B virus (HBV) infection, genotypes and drug resistance mutations in human immunodeficiency virus-positive patients in Northwest Ethiopia.
Abstract: All HIV/HBV positive cases were on ART with anti-HBV activity (i.e., 3TC) and 3TC associated HBV DRMs (i.e., rtV173L, rtL180M, and rtM204V) were detected in 7/13 (53.8%) subjects.
Abstract: The detected resistance mutations were rtL180M (14/15 patients) and rtM204V/I (15/15).
Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B.
PMID: 27313669
2016
Experimental and therapeutic medicine
Abstract: At the initiation of sequential monotherapy with ADV, LAM-resistant variants (rtM204V/I and rtL180M) were detected in the three patients.
Abstract: During 30-41 months of ADV-ETV combination therapy, viral load reduction was 2.59-3.28 log10 copies/ml; ADV-resistant variants rtA181T/V and rtN236T were undetectable following 11-24 months of combination therapy; and rtL180M and rtM204I/V remained dominant in the viral population.
Abstract: In conclusion, the results of the present study suggested that, in patients with LAM and ADV-resista
Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy.
PMID: 27446286
2016
Experimental and therapeutic medicine
Abstract: The turn of secondary protein structure of P gene changed to beta sheet when a rtM204V mutation occurred, and no change of secondary protein structure was associated with the rtL180M mutation.
Abstract: Two patients with rtM204V + rtL180M belonged to genotype C and another patient with rtL180M alone belonged to genotype D.
Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B.
Abstract: T54N, L80I/V, I91L/V, L180M, M204I/V, Q215P/S, and F221Y/S showed the highest number of mutations in all groups with different frequencies.
Result: As was expected, M204I/V showed the highest frequency in all of the groups that were studied (the highest and the lowest values were 22.4 and 68.7% in groups IV and III, respectively).
Result: They contained the highest frequency of substitutions for residues L180M (43.7%) and M204I/V (68.7%) among all the groups.
Discussion: Studies showed that the failure of therapy due to M204I/V could be
Detection of Anti-Hepatitis B Virus Drug Resistance Mutations Based on Multicolor Melting Curve Analysis.
PMID: 27535686
2016
Journal of clinical microbiology
Abstract: The two-reaction assay had a limit of detection of 5 copies per reaction and could detect a minor mutant population (5% of the total population) with the reverse transcriptase M204V amino acid mutation in the presence of the major wild-type population when the overall concentration was 104 copies/mul.
HBV mutation literature information.
PMID: 
2017
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT